Airs Medical vs Nanox.AI

Nanox's AI page claims 7 FDA clearances and 2 CE marks, while openFDA lists 12 records under the Zebra, Nanoxai and Nano-X AI applicant names. The current products on the page are HealthCCSng for coronary calcium, HealthOST for vertebral height loss and bone density, and HealthFLD for liver density, all run on CT scans acquired for other reasons. A radiology department with large CT volume and an opportunistic screening program takes Nanox. An MRI center with a backlog is the audience for Airs, which cites 1,700+ to 2,000+ institutions and whose FDA record includes SwiftSight-BodyComposition alongside SwiftMR.

Corewell Health's case study on the Nanox page cites nearly 4,000 new coronary calcification patients in 2023 against 268 in the prior two years. A 2025 Diagnostics clinical validation of HealthOST, on outpatient chest and abdomen CT for incidental vertebral compression fractures, reported 92.0% sensitivity at the 20% height-loss threshold, and the abstract's specificity figure starts at 52.7%.